Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease

Dobson, L.S. , Lorigan, P.C., Coleman, R.E. orcid.org/0000-0002-4275-1043 et al. (1 more author) (2000) Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. British Journal of Cancer, 82 (9). pp. 1547-1552. ISSN 0007-0920

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2000 Cancer Research Campaign. Twelve months after publication in an issue of BJC, all content is made freely available to readers via PubMed Central and the BJC website (www.bjcancer.com) under the terms of BJC’s attribution, non commercial, share alike licence (CC BY NC SA)
Keywords: gestational trophoblastic disease; combination chemotherapy
Dates:
  • Published: May 2000
  • Published (online): 4 April 2000
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 16 Dec 2016 11:06
Last Modified: 16 Dec 2016 11:37
Published Version: https://doi.org/10.1054/bjoc.2000.1176
Status: Published
Publisher: Cancer Research UK
Refereed: Yes
Identification Number: https://doi.org/10.1054/bjoc.2000.1176

Share / Export

Statistics